Rise Advisors’s Standard BioTools LAB Stock Holding History

Rise Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-463	Closed	-$602	–	827
2025 Q3	$602	Hold	463	–	–	﹤0.01%	1366
2025 Q2	$556	Buy	+463	New	+$513	﹤0.01%	1389

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Rise Advisors's LAB Position: Q4 2025 in Review

Rise Advisors sold out of Standard BioTools (LAB) in Q4 2025, closing a stake of 463 shares — an estimated $602 sold.

Rise Advisors first reported a position in LAB in Q2 2025 and held it in 2 quarters. The position peaked at $602 in Q3 2025. 159 funds tracked by Wall St. Rank hold LAB as of Q4 2025.

Rise Advisors reported no remaining Standard BioTools position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 463 Standard BioTools shares in Q4 2025, an estimated $602.
Rise Advisors first reported a position in Standard BioTools in Q2 2025 and held it in 2 quarters.
Rise Advisors's Standard BioTools position peaked at $602 in Q3 2025.
159 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.